Menlo Park, CA, United States of America

Frank M Longo

This inventor holds 14 USPTO granted patents and 15 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignees: University of California, Pharmatrophix, Inc., The United States Government as Represented by the Department of Veterans Affairs. Active years: 1992-2022.

USPTO Granted Patents = 14 (Patent Applications = 15)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 1.8

ph-index = 5

Forward Citations = 140(Granted Patents)

Location History:

San Francisco, CA (US) (1992 - 2004)
Menlo Park, CA (US) (2010 - 2022)

Company Filing History:

7 out of 15,988

University of California

The United States Government as Represented by the Department of Veterans Affairs

patents

4. 4 out of 1,325

The University of North Carolina at Chapel Hill

where one patent can have more than one assignee

Years Active: 1992-2022

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11225467 - Crystalline forms of neurotrophin mimetic compounds and their salts (2022-01-18),

2. 10532988 - Crystalline forms of neurotrophin mimetic compounds and their salts (2020-01-14),

3. 10273219 - Crystalline forms of neurotrophin mimetic compounds and their salts (2019-04-30),

4. 9884833 - Crystalline forms of neurotrophin mimetic compounds and their salts (2018-02-06),

5. 9828332 - Non-peptide BDNF neurotrophin mimetics (2017-11-28),

6. 9828330 - Non-peptide BDNF neurotrophin mimetics (2017-11-28),

7. 9604907 - Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics (2017-03-28),

8. 9271986 - Crystalline forms of neurotrophin mimetic compounds and their salts (2016-03-01),

9. 8916556 - Pharmaceutical formulations comprising neurotrophin mimetics (2014-12-23),

10. 8686045 - Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics (2014-04-01),

11. 7723328 - Methods of facilitating cell survival using neurotrophin mimetics (2010-05-25),

12. 6696407 - Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF (2004-02-24),

13. 5958875 - Synthetic peptides derivatives with nerve growth factor-like (1999-09-28),

14. 5134121 - Nerve growth factor peptides (1992-07-28),

Title: **The Innovations of Frank M. Longo: A Pioneer in Neurotrophin Mimetic Compounds**

Introduction

Frank M. Longo, an innovative inventor based in Menlo Park, California, has made notable contributions to the field of biotechnology. With an impressive portfolio consisting of 14 patents, he has played a significant role in advancing therapeutic compounds aimed at improving health outcomes. His work reflects a deep commitment to scientific research and a keen understanding of the intersections between chemistry and medicine.

Latest Patents

Among his latest contributions, Longo has developed crystalline forms of neurotrophin mimetic compounds and their salts. This invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide, along with various salts. The significance of these crystalline forms lies in their therapeutic applications, which encompass the treatment of neurodegenerative conditions. Additionally, Longo's research provides compositions that incorporate these crystalline forms, emphasizing their potential in therapeutic uses.

Career Highlights

Throughout his career, Longo has associated himself with notable organizations that have enriched his expertise and expanded his reach in the biotechnology sector. He has worked with the University of California and Pharmatrophix, Inc., contributing to cutting-edge research and innovations in biomedicine. These experiences not only showcase his capabilities as an inventor but also his dedication to the advancement of scientific knowledge.

Collaborations

In the course of his career, Frank M. Longo has collaborated with esteemed colleagues such as Rajgopal Munigeti and Stephen M. Massa. These partnerships highlight the importance of teamwork in the research field, allowing for a synergistic approach to solving complex scientific challenges. Their collaborative efforts have played a vital role in bringing new inventions to fruition and enhancing the therapeutic landscape.

Conclusion

Frank M. Longo's contributions to the field of neurotrophin mimetic compounds underscore his importance as an inventor in the realm of biotechnology. With an impressive patent portfolio and a track record of collaboration, he has set a benchmark for aspiring innovators. His ongoing research continues to pave the way for significant advancements in therapeutic applications, ultimately aiming to improve the quality of life for many individuals.